LMTK2

Across TCGA pan-cancer cohorts, LMTK2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LMTK2 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LMTK2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LMTK2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

UCEC, LUAD, and GBM are the cancer types where LMTK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.945	0.476	<.001	30	view →
LUAD	OS	Tertile	III,IV	0.722	0.206	.013	19	view →
GBM	DFS	Median	All	0.799	0.646	.001	17	view →
CCRCC	OS	Tertile	II,III,IV	1.000	0.802	.019	4	view →
HNSC	OS	Median	III,IV	0.948	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LMTK2–UCEC (DFS)

Open the UCEC breakdown →